GlassScriptPhysician profile
Lindsey M Turner
NPI 1093027385
$3,006.54
in general payments reported to CMS, 2019-2025
37 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $351 · 2021: $852 · 2022: $542 · 2023: $495 · 2024: $147 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,190.49 | 2019-2025 | Liletta, Ubrelvy, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $146.45 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Takeda Pharmaceuticals U.S.A., INC. | $130.08 | 2021-2022 | |
| Daiichi Sankyo INC. | $122.44 | 2020-2022 | |
| Astellas Pharma US INC | $118.26 | 2021-2025 | Veozah, Myrbetriq |
| Vertical Pharmaceuticals, LLC | $114.56 | 2019 | |
| Pfizer INC. | $109.55 | 2019-2025 | |
| Exeltis, USA INC. | $84.31 | 2021-2025 | Slynd |
| Avion Pharmaceuticals | $72.58 | 2020-2023 | Balcoltra |
| Merck Sharp & Dohme LLC | $71.79 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $69.43 | 2021 | |
| Amgen INC. | $66.72 | 2019-2022 | |
| Organon LLC | $57.77 | 2023-2025 | Jada System |
| Medtronic, INC. | $57.77 | 2023 | Sonicision |
| Evofem Biosciences, INC. | $51.25 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $50.53 | 2019-2021 | |
| Eisai INC. | $43.41 | 2020-2021 | |
| Therapeuticsmd, INC. | $38.71 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $31.55 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $30.26 | 2023-2024 | Myfembree, Gemtesa |
| Ethicon US, LLC | $30.21 | 2023 | Surgiflo Hemostatic Matrix |
| Sage Therapeutics, LLC | $29.45 | 2024-2025 | Zurzuvae |
| Radius Health, INC. | $27.47 | 2020-2021 | |
| Myovant Sciences INC. | $27.29 | 2022 | |
| Zyla Life Sciences, INC. | $26.59 | 2020 | |
| Smith+Nephew, INC. | $24.84 | 2022 | |
| Dysis Medical, INC. | $23.21 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Bayer Healthcare Pharmaceuticals INC. | $22.99 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.32 | 2022 | |
| Dexcom, INC. | $16.22 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $16.15 | 2022 | |
| Lilly USA, LLC | $16.11 | 2024 | Zepbound |
| Novo Nordisk INC | $15.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.40 | 2020 | |
| Davol INC. | $15.22 | 2022 | |
| Scynexis, INC. | $13.78 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.